Afficher le profil
Base
| Nom | Bernard FROMENTY |
| Grade | |
| Equipe | |
| Adresse | CHU Pontchaillou – 2 rue Henri Le Guilloux – 35033 Rennes Cedex |
| Téléphone | |
| Skills | Expertise in hepatotoxicity induced by xenobiotics including ethanol and drugs, in particular in the context of obesity and nonalcoholic fatty liver disease (NAFLD). |
| Research topics and scientific objectives | The main objectives of my research is to determine the mechanisms of hepatotoxity induced by different xenobiotics including ethanol and drugs such as amiodarone and acetaminophen (APAP). The role of mitochondrial dysfunction and oxidative stress is more specifically studied. In addition, my investigations try to decipher the mechanisms whereby some xenobiotics such ethanol and APAP are more toxic in the context of obesity and nonalcoholic fatty liver disease (NAFLD). The cytochrome P450 2E1 (CYP2E1) is particularly investigated in these studies since the activity of this enzyme is enhanced during NAFLD, thus increasing the generation of toxic reactive metabolites. |
| Education and main positions held | Diplomas Positions Team leadership: 2006-2009: Leader of Team n°5 (Mitochondria and liver), INSERM Unit 773 (Centre de Recherche Biomédicale Bichat-Beaujon-CRB3 – Paris; Head: Marc Laburthe). 2010-2016: Leader of Team n°3 (Hepatotoxicity of xenobiotics: mechanisms and modulation by obesity), INSERM Unit 991 (Liver, Metabolisms and Cancer- Rennes; Head: Bruno Clément). 2017-2021: Coleader with Dr Anne Corlu of the EXPRES Team, INSERM Unit 1241, Institu NuMeCan (Nutrition, Metabolisms and Cancer – Rennes; Head Bruno Clément). 2022-2027: Coleader with Dr Anne Corlu of the EXPRES Team, INSERM Unit 1241, Institu NuMeCan (Nutrition, Metabolisms and Cancer – Rennes; Head Olivier Loréal). |
| Current projects | Several projects pertaining to the toxic effects of different xenobiotics (drugs, ethanol and environmental contaminants) in normal and steatotic HepaRG cells and/or in lean and obese mice. |
| Selected publications | 1. Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J. Hepatol. 2022 (in press). https://doi.org/10.1016/j.jhep.2022.09.020 2. Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. Int. J. Mol. Sci. 2022 Jan 19;23(3):1062. 3. Massart J, Begriche K, Hartman JH, Fromenty B. Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver. Cells 2022 Jan 15;11(2):288. 4. Allard J, Bucher S, Massart J, Ferron PJ, Le Guillou D, Loyant R, Daniel Y, Launay Y, Buron N, Begriche K, Borgne-Sanchez A, Fromenty B. Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol. Toxicol. 2021;37:151-175. 5. Bucher S, Begriche K, Catheline D, Trak-Smayra V, Tiaho F, Coulouarn C, Pinon G, Lagadic-Gossmann D, Rioux V, Fromenty B. Moderate chronic ethanol consumption exerts beneficial effects on nonalcoholic fatty liver in mice fed a high-fat diet. Possible role of higher formation of triglycerides enriched in monounsaturated fatty acids. Eur. J. Nutr. 2020;59:1619–1632. |